Keith Karcher

2.4k total citations
27 papers, 1.5k citations indexed

About

Keith Karcher is a scholar working on Psychiatry and Mental health, Pharmacology and Clinical Psychology. According to data from OpenAlex, Keith Karcher has authored 27 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Psychiatry and Mental health, 6 papers in Pharmacology and 6 papers in Clinical Psychology. Recurrent topics in Keith Karcher's work include Schizophrenia research and treatment (9 papers), Attention Deficit Hyperactivity Disorder (5 papers) and Bipolar Disorder and Treatment (5 papers). Keith Karcher is often cited by papers focused on Schizophrenia research and treatment (9 papers), Attention Deficit Hyperactivity Disorder (5 papers) and Bipolar Disorder and Treatment (5 papers). Keith Karcher collaborates with scholars based in United States, Belgium and United Kingdom. Keith Karcher's co-authors include Mariëlle Eerdekens, Samuel J. Keith, Michael D. Lesem, John M. Kane, Jean‐Pierre Lindenmayer, Michelle Kramer, Fred Grossman, Stuart Kushner, О. Гефверт and S Martin and has published in prestigious journals such as Gastroenterology, American Journal of Psychiatry and Neurology.

In The Last Decade

Keith Karcher

25 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Keith Karcher United States	17	1.2k	264	244	214	179	27	1.5k
Tamás Treuer United States	21	1.1k 0.9×	306 1.2×	77 0.3×	137 0.6×	47 0.3×	88	1.4k
Jamie Kane United States	6	887 0.7×	284 1.1×	281 1.2×	144 0.7×	81 0.5×	13	1.2k
Seema Quraishi United Kingdom	14	1.0k 0.8×	239 0.9×	177 0.7×	98 0.5×	77 0.4×	20	1.2k
Siow‐Ann Chong Singapore	23	795 0.7×	201 0.8×	164 0.7×	75 0.4×	101 0.6×	43	1.1k
Wayne Macfadden United States	20	1.5k 1.3×	188 0.7×	74 0.3×	488 2.3×	85 0.5×	43	2.2k
Halldóra Jónsdóttir Norway	19	1.3k 1.0×	304 1.2×	217 0.9×	118 0.6×	32 0.2×	24	1.6k
Maju Mathews United States	18	702 0.6×	204 0.8×	99 0.4×	300 1.4×	76 0.4×	73	1.0k
Haranath Parepally United States	16	986 0.8×	320 1.2×	204 0.8×	107 0.5×	79 0.4×	24	1.2k
Joseph McEvoy United States	7	838 0.7×	231 0.9×	274 1.1×	130 0.6×	70 0.4×	13	1.0k
Peter F.J. Schulte Netherlands	17	799 0.7×	211 0.8×	121 0.5×	107 0.5×	130 0.7×	47	1.1k

Countries citing papers authored by Keith Karcher

Since Specialization

Citations

This map shows the geographic impact of Keith Karcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Karcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Karcher more than expected).

Fields of papers citing papers by Keith Karcher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith Karcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Karcher. The network helps show where Keith Karcher may publish in the future.

Co-authorship network of co-authors of Keith Karcher

This figure shows the co-authorship network connecting the top 25 collaborators of Keith Karcher. A scholar is included among the top collaborators of Keith Karcher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith Karcher. Keith Karcher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morrison, Randall L., Jaskaran Singh, Ella Daly, et al.. (2024). Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies. The International Journal of Neuropsychopharmacology. 27(11). 2 indexed citations

Antozzi, Carlo, Jeffrey T. Guptill, Vera Bril, et al.. (2023). Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis. Neurology. 102(2). e207937–e207937. 30 indexed citations

Ramchandren, Sindhu, Carlo Antozzi, Vera Bril, et al.. (2022). Serum Autoantibody Lowering by the Anti-FcRn Monoclonal Antibody, Nipocalimab, Correlates With Clinical Improvement in Generalized Myasthenia Gravis Patients. Neurology. 99(23_Supplement_2). 2 indexed citations

Howard, Robert, Sergi G. Costafreda, Keith Karcher, et al.. (2016). Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients. The British Journal of Psychiatry. 209(5). 378–384. 16 indexed citations

Chen, Yeung-Jen, et al.. (2015). Tapentadol immediate-release for acute postbunionectomy pain: a phase 3, randomized, double-blind, placebo-controlled, parallel-group study in Taiwan. Current Medical Research and Opinion. 31(11). 2001–2009. 8 indexed citations

Kent, Justine, David Hough, Jaskaran Singh, Keith Karcher, & Gahan Pandina. (2013). An Open-Label Extension Study of the Safety and Efficacy of Risperidone in Children and Adolescents with Autistic Disorder. Journal of Child and Adolescent Psychopharmacology. 23(10). 676–686. 33 indexed citations

Kent, Justine, Stuart Kushner, Xiaoping Ning, et al.. (2012). Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study. Journal of Autism and Developmental Disorders. 43(8). 1773–1783. 87 indexed citations

Pandina, Gahan, Stuart Kushner, Keith Karcher, & Magali Haas. (2012). An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia. Child and Adolescent Psychiatry and Mental Health. 6(1). 23–23. 17 indexed citations

Alphs, Larry, Srihari Gopal, Keith Karcher, et al.. (2011). Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases. Current Drug Safety. 6(1). 43–45. 15 indexed citations

10.

Quiroz, Jorge A., Lakshmi N. Yatham, Joseph Palumbo, et al.. (2010). Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder. Biological Psychiatry. 68(2). 156–162. 104 indexed citations

11.

Haas, Magali, Keith Karcher, & Gahan Pandina. (2008). Treating Disruptive Behavior Disorders with Risperidone: A 1-Year, Open-Label Safety Study in Children and Adolescents. Journal of Child and Adolescent Psychopharmacology. 18(4). 337–345. 22 indexed citations

12.

Keks, Nicholas A, M. Ingham, Akbar Ali Khan, & Keith Karcher. (2007). Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. The British Journal of Psychiatry. 191(2). 131–139. 75 indexed citations

13.

Hirschfeld, Robert M. A., Mariëlle Eerdekens, Amir H Kalali, et al.. (2005). An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder. International Clinical Psychopharmacology. 21(1). 11–20. 32 indexed citations

14.

Croonenberghs, Jan, et al.. (2005). ANTIPSYCHOTICS IN DISRUPTIVE BEHAVIOR DISORDERS AND ADHD. Journal of the American Academy of Child & Adolescent Psychiatry. 44(10). 970–971. 1 indexed citations

15.

Hirschfeld, Robert M. A., Paul E. Keck, Michelle Kramer, et al.. (2004). Rapid Antimanic Effect of Risperidone Monotherapy: A 3-Week Multicenter, Double-Blind, Placebo-Controlled Trial. American Journal of Psychiatry. 161(6). 1057–1065. 177 indexed citations

16.

Ab, Smulevich, Sumant Khanna, Mariëlle Eerdekens, et al.. (2004). Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. European Neuropsychopharmacology. 15(1). 75–84. 120 indexed citations

17.

Fleischhacker, W. Wolfgang, Mariëlle Eerdekens, Keith Karcher, et al.. (2003). Treatment of Schizophrenia With Long-Acting Injectable Risperidone. The Journal of Clinical Psychiatry. 64(10). 1250–1257. 253 indexed citations

18.

Kane, John M., Mariëlle Eerdekens, Jean‐Pierre Lindenmayer, et al.. (2003). Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic. American Journal of Psychiatry. 160(6). 1125–1132. 379 indexed citations

19.

Johanson, John F., Philip B. Miner, Henry P. Parkman, et al.. (2000). Prucalopride (PRU) significantly improves symptoms (SX) associated with chronic constipation (CC). Gastroenterology. 118(4). A1085–A1085. 1 indexed citations

20.

Corren, Jonathan, Gary S. Rachelefsky, Sheldon L. Spector, et al.. (1999). Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions. Journal of Allergy and Clinical Immunology. 103(4). 574–580. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact